Lilly's Pipeline: Retatrutide and the Triple Agonist Thesis The most closely watched pipeline asset in the GLP-1 space is Lilly's retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
Key trends to watch: State alignment : More states are moving toward flexible telehealth models that maintain patient safety while improving access NP/PA authority : Several states are considering bills to expand nurse practitioner prescribing authority Insurance coverage : More insurers are beginning to cover both telehealth visits and GLP-1 medications New medications : As more weight management medications enter the market, telehealth will adapt to incorporate them Conclusion: Making Informed Decisions GLP-1 medications represent a significant advancement in obesity treatment, and telehealth has made these treatments more accessible than ever
250ml size provides 50 x servings (250mg Glutathione)
For researchers studying the boundaries of pharmacological weight loss, NAFLD, or glucagon receptor biology, Retatrutide offers mechanistic depth unavailable in any dual agonist
However, many vegetables are low in fiber and packed with fiber to help you feel full